$MDGN (Medgenics, Inc.)

$MDGN {{ '2016-06-06T18:06:13+0000' | timeago}} • Announcement

$MDGN said it has entered into a collaboration with Kyowa Hakko Kirin for the development and commercialization of Kyowa's first-in-class anti-LIGHT monoclonal antibody. The anti-LIGHT monoclonal antibody is a Phase 2-ready biologic with available clinical supply.

$AMAG {{ '2018-01-08T15:32:45+0000' | timeago}} • Announcement

Pharma firm $AMAG said it expects double-digit revenue growth in fiscal 2017, and strong bottomline cash generation. The company expects 4Q17 revenues to be between $155MM and $162MM, and sees an operating loss of $6-$16MM. FY17 revenue is estimated to be in the $607-$614MM range. Full year operating loss is forecasted between $292MM and $302MM.

$ACOR {{ '2018-01-08T12:56:05+0000' | timeago}} • Announcement

Bio-pharmaceuticals company $ACOR has reported net sales of $542MM for fiscal 2017. For fiscal 2018, the company expects net sales to be in the range of $330MM to $350MM. R&D and SG&A operating expenses, on an adjusted basis, is forecasted in the $270-$290MM range.

$SGEN {{ '2017-12-11T16:30:10+0000' | timeago}} • Announcement

$SGEN and $BMY highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) in relapsed or refractory classical Hodgkin lymphoma (HL).

$ACOR {{ '2017-12-07T14:24:01+0000' | timeago}} • Announcement

$ACOR announced the resubmission of its New Drug Application (NDA) for INBRIJA to the US FDA. INBRIJA is an investigational treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. FDA is expected to inform $ACOR within 74 days if the submission has been deemed complete and permits a full review.

$ACOR {{ '2017-11-20T13:09:44+0000' | timeago}} • Announcement

$ACOR stops developing its Parkinson’s disease drug tozadenant. This decision comes a week after the drugmaker reported five deaths in key studies testing the treatment. The company would stop enrolling patients in two long-term safety trials after it found seven cases of sepsis in mid- and late-stage trials.

$ACOR {{ '2017-11-17T15:46:22+0000' | timeago}} • Announcement

$ACOR announced a $40MM royalty monetization with HealthCare Royalty Partners (HCR) and a $13MM royalty monetization with H. Lundbeck A/S. H. Lundbeck and $ACOR have amended the license agreement for Selincro to eliminate future royalty and milestone obligations on sales of Selincro outside of the United States.

$ACOR {{ '2017-11-15T12:23:57+0000' | timeago}} • Announcement

$ACOR said it has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

$ACOR {{ '2017-11-15T12:23:21+0000' | timeago}} • Announcement

$ACOR lifted frequency of blood cell count monitoring for participants to weekly in Phase 3 program of tozadenant for Parkinson's disease. $ACOR took this action in response to cases of agranulocytosis, possibly drug-related, and in some cases associated with sepsis and death. Agranulocytosis is absence of white blood cells, which fight infection.

$AMAG {{ '2017-11-06T14:14:12+0000' | timeago}} • Announcement

Pharma company $AMAG said data from its phase-3 study of Feraheme and Injectafer showed that patients treated with Feraheme were markedly less likely to develop severe hypophosphatemia compared to those treated with Injectafer. The study was conducted to assess the impact of the use of intravenous iron treatment on phosphate metabolism.

$TECH {{ '2017-10-31T15:32:14+0000' | timeago}} • Announcement

$TECH has declared a quarterly dividend of $0.32 per share on its common stock. The dividend is payable on November 24, 2017, to shareholders of record on November 10, 2017.

$ARAY {{ '2017-10-19T16:41:01+0000' | timeago}} • Announcement

$ARAY said that the Court of Appeal of Nantes has rejected the appeal filed by Varian Medical Systems opposing the purchase of the Accuray TomoTherapy System by University Hospital of Tours (CHU). This marks the final appeal by Varian in their efforts to overturn CHU's tender award and block their use of the TomoTherapy technology.

$AMED {{ '2017-10-09T14:58:01+0000' | timeago}} • Announcement

Healthcare company $AMED has promoted Scott Ginn to the post of CFO, effective immediately. He will be replacing Gary Willis who has resigned to join another firm. Before joining Amedisys, Ginn had served business advisory firm Postlethwaite & Netterville as a Director.

$AMED {{ '2017-10-02T13:33:59+0000' | timeago}} • Announcement

$AMED's subsidiary Associated Home Care closed on its acquisition of Intercity Home Care, a personal care provider headquartered in Malden, Massachusetts. Associated Home Care acquired substantially all assets of Intercity Home Care.

$AMAG {{ '2017-09-29T12:41:24+0000' | timeago}} • Announcement

$AMAG announced the appointment of Tracy Palmer Berns as Chief Compliance Officer, with immediate effect. She will report to Joseph Vittiglio, General Counsel and SVP of Legal Affairs and Quality. Berns was the VP of Ethics and Compliance at the Minimally Invasive Therapies Group at $MDT.

$CELG {{ '2017-09-19T18:41:27+0000' | timeago}} • Announcement

After collaborating with $CELG for almost a decade, $XLRN amended its development and commercial agreement with Celgene for the investigational drug Sotatercept. Acceleron will develop and market Sotatercept in the pulmonary hypertension field. Celgene will be eligible to receive royalties on global net sales in that field.

$JEC {{ '2017-09-19T13:26:00+0000' | timeago}} • Announcement

$JEC was selected by $AERI to provide engineering, procurement and construction management services (EPCM) for Aerie’s first pharmaceutical manufacturing facility, located in the Industrial Development Authority (IDA)’s advanced technology building in Athlone, Republic of Ireland.

$AMAG {{ '2017-09-07T13:58:27+0000' | timeago}} • Announcement

$AMAG appointed Laura Williams as SVP of clinical development, effective immediately. She will report to Julie Krop, M.D., chief medical officer and SVP of clinical development and regulatory affairs at $AMAG. Prior to joining $AMAG, she served as VP of clinical development at Myovant Sciences.

$AMED {{ '2017-08-31T15:10:17+0000' | timeago}} • Announcement

Healthcare company $AMED’s subsidiary, Associated Home Care, has signed a definitive agreement to acquire Intercity Home Care, a personal care provider. Under the terms of agreement, Associated Home Care will acquire substantially all of the assets of Intercity Home Care. The transaction is expected to close by Oct 1, 2017.

$ACOR {{ '2017-08-29T11:50:07+0000' | timeago}} • Announcement

$ACOR received a Refusal to File (RTF) letter from the FDA regarding its New Drug Application (NDA) for Inbrija (CVT-301, levodopa inhalation powder). Inbrija is an investigational treatment for symptoms of OFF periods in people with Parkinson's disease taking a carbidopa/levodopa regimen.

$AMAG {{ '2017-08-08T16:06:08+0000' | timeago}} • Announcement

$AMAG appointed Oscar Sanchez as VP of quality effective immediately. He will report to Joseph Vittiglio, general counsel and SVP of legal affairs and quality.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
ACRX (AcelRx Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 9:30pm
AERI (Aerie Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 10:00pm
AKAO (Achaogen, Inc.)
Wednesday, November 8 2017 - 9:30pm
AMED (Amedisys Inc.)
Wednesday, November 8 2017 - 4:00pm
AGEN (Agenus Inc.)
Tuesday, November 7 2017 - 4:00pm
XLRN (Acceleron Pharma, Inc.)
Tuesday, November 7 2017 - 1:00pm
AMAG (AMAG Pharmaceuticals, Inc.)
Thursday, November 2 2017 - 12:00pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
TECH (Bio-Techne Corp.)
Tuesday, October 31 2017 - 1:00pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, October 31 2017 - 12:30pm
SGEN (Seattle Genetics, Inc.)
Thursday, October 26 2017 - 8:30pm
ARAY (Accuray Incorporated)
Tuesday, October 24 2017 - 8:30pm
ARAY (Accuray Incorporated)
Tuesday, August 22 2017 - 8:30pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
ACHN (Achillion Pharmaceuticals, Inc.)
Tuesday, August 8 2017 - 8:05pm
TECH (Bio-Techne Corp.)
Tuesday, August 8 2017 - 1:00pm
XLRN (Acceleron Pharma, Inc.)
Thursday, August 3 2017 - 9:00pm
AKAO (Achaogen, Inc.)
Thursday, August 3 2017 - 8:30pm

AlphaGraphics you may like